Rohan does make those statements, but i think they are more general. PYC targets very very specific genetic diseases (RP11 is about 3% of all RP for example) and PYC has usually got a cure planned, not a treatment. So I dont believe there are actual real competitors out there that are doing exactly what we are doing. They are in the same space, but for different diseases usually.
His statements are about other companies doing similar things but for different illnesses, and the comparisons with respect to mcap suggest we are about half price! ( or 1/4 price!)
Question for holders about exclusivity., page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $387.0K | 2.178M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 77908 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 225408 | 5 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |